Disease Stage and Plasma Levels of Cytokines in Huntington's Disease: A 2-Year Follow-Up Study

Author(s):
Bouwens, J.A.; Duijn, E. van; Cobbaert, C.M. (0000-0003-3565-1404); Roos, R.A.C. (0000-0001-5591-1133); Mast, R.C. van der (0000-0002-4516-547X); Giltay, E.J.
Published
2017
Publication type
Article / Letter to editor

Abstract

It has been shown that plasma levels of cytokines are elevated in Huntington's disease (HD) gene expansion carriers when compared with controls and are higher in advanced disease stages.[1] To test the hypothesis that plasma cytokines may serve as a biomarker of disease progression,[2] levels of proinflammatory and anti-inflammatory cytokines were measured in different disease stages at baseline and during a 2-year follow-up.

In the present study, in the total group of HD gene expansion carriers, an increase was found TNF-α and IL-10 levels during the 2-year follow-up. This may reflect a reactive elevation of anti-inflammatory cytokines after the initial proinflammatory response.

Date issued
2017-07-31
Language
English
Is part of
Movement Disorders (2017), Vol. 32, no. 7, p. 1103-1104
hdl
1887/114469
doi
10.1002/mds.26950